STC-8123
/ Schrodinger
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 12, 2022
Schrödinger Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at American Association of Cancer Research 2022 Annual Meeting
(Businesswire)
- "Schrödinger is on track to select a Wee1 development candidate later this year. Subject to completion of the preclinical data packages, Schrödinger anticipates submitting an Investigation New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) in 2023...These molecules demonstrate superior kinase selectivity compared to other known Wee1 inhibitors in a broad kinase panel. In multiple preclinical models, a representative compound, STC-8123, was well tolerated and demonstrated sustained pharmacodynamic and pharmacokinetic properties. The anti-tumor effects of STC-8123 were maintained during dosing holidays while allowing full recovery of mechanism-based hematological effects, likely due to its sustained plasma concentrations and high exposure in tumors. Schrödinger’s advanced Wee1 program compounds maintained potency, selectivity and anti-tumor activity with no detectable time-dependent inhibition of CYP3A4, a key liver enzyme."
IND • Preclinical
1 to 1
Of
1
Go to page
1